BR112023017490A2 - Métodos de tratamento de dermatite atópica com anticorpos anti il-13 - Google Patents

Métodos de tratamento de dermatite atópica com anticorpos anti il-13

Info

Publication number
BR112023017490A2
BR112023017490A2 BR112023017490A BR112023017490A BR112023017490A2 BR 112023017490 A2 BR112023017490 A2 BR 112023017490A2 BR 112023017490 A BR112023017490 A BR 112023017490A BR 112023017490 A BR112023017490 A BR 112023017490A BR 112023017490 A2 BR112023017490 A2 BR 112023017490A2
Authority
BR
Brazil
Prior art keywords
atopic dermatitis
treatment
methods
antibodies
antigen
Prior art date
Application number
BR112023017490A
Other languages
English (en)
Inventor
Cristian Rodriguez
Erin Babcock
Sarah Harris
Original Assignee
Receptos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptos Llc filed Critical Receptos Llc
Publication of BR112023017490A2 publication Critical patent/BR112023017490A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

usos de um anticorpo anti-il-13, ou de um fragmento de ligação ao antígeno do mesmo, para o tratamento de dermatite atópica ou para reduzir a incidência de dermatite atópica. o presente relatório descritivo é direcionado a métodos de tratamento de dermatite atópica compreendendo a administração a um indivíduo em necessidade do mesmo uma quantidade terapeuticamente eficaz de um anticorpo anti-il-13, ou fragmento de ligação ao antígeno do mesmo, tratando assim a dermatite atópica no indivíduo.
BR112023017490A 2021-03-17 2022-03-16 Métodos de tratamento de dermatite atópica com anticorpos anti il-13 BR112023017490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162101P 2021-03-17 2021-03-17
PCT/US2022/020518 WO2022197782A1 (en) 2021-03-17 2022-03-16 Methods of treating atopic dermatitis with anti il-13 antibodies

Publications (1)

Publication Number Publication Date
BR112023017490A2 true BR112023017490A2 (pt) 2023-11-07

Family

ID=81326386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017490A BR112023017490A2 (pt) 2021-03-17 2022-03-16 Métodos de tratamento de dermatite atópica com anticorpos anti il-13

Country Status (10)

Country Link
US (1) US11964005B2 (pt)
EP (1) EP4308603A1 (pt)
JP (1) JP2024511078A (pt)
KR (1) KR20240008298A (pt)
CN (1) CN117203232A (pt)
AU (1) AU2022238849A1 (pt)
BR (1) BR112023017490A2 (pt)
CA (1) CA3208011A1 (pt)
IL (1) IL305901A (pt)
WO (1) WO2022197782A1 (pt)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB8826530D0 (en) 1988-11-12 1988-12-14 Ped Capacitors Ltd Electrical capacitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
SE8901889D0 (sv) 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2089362C (en) 1990-08-24 2000-11-21 William D. Huse Methods of synthesizing oligonucleotides with random codons
NZ241119A (en) 1990-12-20 1993-06-25 Ixsys Inc Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1278778A2 (en) 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US20160002326A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
SI3528838T1 (sl) 2016-09-23 2023-10-30 F. Hoffmann-La Roche Ag Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
IL305901A (en) 2023-11-01
AU2022238849A1 (en) 2023-08-31
KR20240008298A (ko) 2024-01-18
JP2024511078A (ja) 2024-03-12
CN117203232A (zh) 2023-12-08
EP4308603A1 (en) 2024-01-24
WO2022197782A1 (en) 2022-09-22
US11964005B2 (en) 2024-04-23
US20220305104A1 (en) 2022-09-29
CA3208011A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
BR112022000377A2 (pt) Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
RU2008152827A (ru) Профилактическое или лекарственное средство для воспалительного заболевания
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
ECSP10010005A (es) Anticuerpos humanos contra cd20 humano y método para utilizarlos
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
RU2010138612A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
BR112015021979A2 (pt) Anticorpos humanos para grem1
HRP20231514T1 (hr) Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
BR112022015363A2 (pt) Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
EA201892409A1 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
MX2022016039A (es) Anticuerpos anti-cd2.
BR112019011350A2 (pt) terapia de combinação
BR112023017490A2 (pt) Métodos de tratamento de dermatite atópica com anticorpos anti il-13
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
BR112022014487A2 (pt) Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo
BR112023023453A8 (pt) Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste, composições farmacêuticas e usos do referido anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste
WO2023130010A8 (en) Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: RECEPTOS LLC (US)